We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).
A study by renowned American economist Edwin Mansfield suggests that 60% of new drugs would not be invented without patent protection, highlighting the importance of patent protection in the pharmaceutical industry today.
Randomised controlled trials (RCTs), where study participants are randomly allocated to an experimental group or a control group, became the ‘gold standard’ of clinical research in the mid-20th century.
This collaborative effort will leverage ProBioGen's cutting-edge GlymaxX® technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.
At present, the use of artificial intelligence to participate in the discovery and design of new drugs has become a hot track for new drug research and development.